The Armchair Analyst examines Cynata's scalable stem cell manufacturing technology and dual clinical catalysts, with Phase 3 osteoarthritis and Phase 2 acute GvHD results expected in the coming months. Analysis includes market opportunity assessment and comparison to sector precedents.